Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD 2.320
-0.130 (-5.31%)
Jul 17, 2026, 4:13 PM AEST
Clarity Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Clarity Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $7.13. The average 1-year stock price forecast is 207.33% higher than the current stock price, while the lowest is $5.20 (+124.14%) and the highest is $8.41 (+262.50%).
Price Target: $7.13 (+207.33%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on May 26, 2026.
Analyst Ratings
The average analyst rating for Clarity Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $8.41 | Buy | Maintains | $8.41 | +262.50% | May 26, 2026 |
| Bell Potter | Bell Potter | Buy Maintains $6.40 → $6.50 | Buy | Maintains | $6.40 → $6.50 | +180.17% | Apr 1, 2026 |
Financial Forecast
Revenue This Year
n/a
from 9.46M
Decreased by -100.00%
Revenue Next Year
933.33K
EPS This Year
-0.30
from -0.20
EPS Next Year
-0.32
from -0.30
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.